Thomas J Kipps

Thomas J Kipps

UNVERIFIED PROFILE

Are you Thomas J Kipps?   Register this Author

Register author
Thomas J Kipps

Thomas J Kipps

Publications by authors named "Thomas J Kipps"

Are you Thomas J Kipps?   Register this Author

100Publications

4423Reads

21Profile Views

A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.

Leuk Lymphoma 2019 Jul 27:1-9. Epub 2019 Jul 27.

c Department of Leukemia, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1643463DOI Listing
July 2019

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

N Engl J Med 2019 06 4;380(23):2225-2236. Epub 2019 Jun 4.

From Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne (K.F., O.A.-S., J.B., A.-M.F., S. Robrecht, B.E., K.-A.K., M.H.), the Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital (V.G.), CECAD (Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases) (M.H.), Center for Molecular Medicine Cologne (M.H.), Cologne, Department III of Internal Medicine, University Hospital Rostock, Rostock (S.B.), Department III of Internal Medicine, Ulm University, Ulm (E.T., S.S.), the Departments of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases, and Tropical Medicine, Klinikum Schwabing, Munich (C.-M.W.), Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel (M.R.), and the Department of Hematology, Oncology, and Rheumatology, Saarland University Medical School, Homburg (S.S.) - all in Germany; Roche Products, Welwyn Garden City, United Kingdom (M.T., M.D., S.W., K.H.); Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod, Russia (O.S.); the Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy (A.M.L.); the Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.P.-I.); the Haematology Department, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (S.O.); First Internal Department, Multiprofile Hospital for Active Treatment Hristo Botev, Vratsa, Bulgaria (L.S.); the Hematology Department, Clinique Victor Hugo, Le Mans, France (K.L.D.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (L.M.F.); the Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen (C.U.N.); Wellington Blood and Cancer Centre, Capital and Coast District Health Board, and Malaghan Institute of Medical Research, Wellington, New Zealand (R.W.); Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (S. Robinson); Moores Cancer Center, University of California San Diego, San Diego (T.J.K.), and Genentech, South San Francisco (M.M.) - both in California; AbbVie, North Chicago, IL (R.H.); and the Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, the Netherlands (A.W.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815281DOI Listing
June 2019

SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia.

Clin Lymphoma Myeloma Leuk 2019 Jun 29;19(6):321-325. Epub 2019 May 29.

Division of Hematology/Oncology, UC San Diego Moores Cancer Center, La Jolla, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.05.013DOI Listing
June 2019

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.

Leuk Lymphoma 2019 Apr 2;60(4):1000-1005. Epub 2018 Oct 2.

f Department of Medicine , University of California San Diego, Moores Cancer Center , San Diego , CA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1512710DOI Listing
April 2019

Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.

Leukemia 2019 03 19;33(3):653-661. Epub 2018 Dec 19.

Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0306-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462876PMC
March 2019

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.

Blood 2019 Feb 28;133(9):990-992. Epub 2018 Dec 28.

CLL Research Consortium, Moores Cancer Center, UC San Diego Health, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-06-857714DOI Listing
February 2019

Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.

Proc Natl Acad Sci U S A 2019 01 8;116(4):1370-1377. Epub 2019 Jan 8.

Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Pharmacology, International Cancer Center, Shenzhen University Health Science Center, 518060 Shenzhen, China;

View Article

Download full-text PDF

Source
http://www.pnas.org/lookup/doi/10.1073/pnas.1816262116
Publisher Site
http://dx.doi.org/10.1073/pnas.1816262116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347692PMC
January 2019

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Cell Stem Cell 2018 Jun;22(6):951-959.e3

Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2018.05.018DOI Listing
June 2018

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma.

Oncotarget 2018 May 15;9(37):24731-24736. Epub 2018 May 15.

Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/25340
Publisher Site
http://dx.doi.org/10.18632/oncotarget.25340DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973864PMC
May 2018

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

N Engl J Med 2018 Mar;378(12):1107-1120

From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713976DOI Listing
March 2018

Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.

Cell Rep 2018 02;22(7):1875-1888

Stanford Comprehensive Cancer Institute and Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.01.053DOI Listing
February 2018

dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia.

Proc Natl Acad Sci U S A 2017 10 18;114(40):10731-10736. Epub 2017 Sep 18.

Department of Cancer Biology and Medical Genetics, The Ohio State University, Columbus, OH 43210;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1708264114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635897PMC
October 2017

Corrigendum to "Wnt5a Signaling in Normal and Cancer Stem Cells".

Stem Cells Int 2017 27;2017:3467360. Epub 2017 Sep 27.

Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzhen 518060, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/3467360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643122PMC
September 2017

Wnt5a Signaling in Normal and Cancer Stem Cells.

Stem Cells Int 2017 12;2017:5295286. Epub 2017 Apr 12.

Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzhen 518060, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/5295286DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405594PMC
April 2017

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

J Clin Oncol 2017 Mar 17;35(8):826-833. Epub 2017 Jan 17.

Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California San Diego, San Diego, CA; Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, and Gary B. Gordon, AbbVie, Chicago, IL; Ahmed Hamed Salem, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Franklin Peale, Genentech, South San Francisco, CA; John F. Gerecitano, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455685PMC
March 2017

hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.

ACS Chem Biol 2017 02 27;12(2):444-455. Epub 2016 Dec 27.

Division of Biomedical Sciences, School of Medicine, University of California, Riverside , 900 University Avenue, Riverside, California 92521, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschembio.6b00962DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320539PMC
February 2017

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Lancet Oncol 2017 Feb 13;18(2):230-240. Epub 2017 Jan 13.

Victorian Comprehensive Cancer Centre, Parkville, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Parkville, Melbourne, VIC, Australia; Department of Clinical Haematology and BMT, The Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia; Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30012-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316338PMC
February 2017

Chronic lymphocytic leukaemia.

Nat Rev Dis Primers 2017 01 19;3:16096. Epub 2017 Jan 19.

CLL Research and Treatment Program, Feinstein Institute for Medical Research, Northwell Health, New Hyde Park, New York, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrdp201696
Publisher Site
http://dx.doi.org/10.1038/nrdp.2016.96DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336551PMC
January 2017

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.

Cancer Cell 2016 Nov 3;30(5):750-763. Epub 2016 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney Street, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.10.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127278PMC
November 2016

Selectivity in Small Molecule Splicing Modulation.

ACS Chem Biol 2016 10 8;11(10):2716-2723. Epub 2016 Aug 8.

The Moores Cancer Center, University of California San Diego , La Jolla, California 92093, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschembio.6b00399DOI Listing
October 2016

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

Blood 2016 09 1;128(12):1609-13. Epub 2016 Aug 1.

Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-04-709519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291297PMC
September 2016

How Do Targeted Therapies Change the Management of Indolent Lymphomas?

Oncology (Williston Park) 2016 09;30(9):859-60

View Article

Download full-text PDF

Source
September 2016

Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias.

Oncotarget 2016 08;7(34):54174-54182

Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338916PMC
August 2016

Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer.

Proc Natl Acad Sci U S A 2016 May 11;113(18):5071-6. Epub 2016 Apr 11.

Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210; Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;

View Article

Download full-text PDF

Source
http://www.pnas.org/content/113/18/5071.full.pdf
Web Search
http://dx.doi.org/10.1073/pnas.1604266113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983805PMC
May 2016

The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands.

ChemMedChem 2016 05 4;11(10):1097-106. Epub 2016 May 4.

Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, CA, 92521, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.201600039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271563PMC
May 2016

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.

PLoS One 2015 1;10(6):e0128151. Epub 2015 Jun 1.

Pediatrics, Children's Cancer Hospital, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0128151PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451012PMC
April 2016

Ibrutinib for Chronic Lymphocytic Leukemia.

N Engl J Med 2016 04;374(16):1594-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1600328DOI Listing
April 2016

Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more.

Best Pract Res Clin Haematol 2016 03 20;29(1):15-29. Epub 2016 Aug 20.

Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, USA; CLL Research Consortium, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.08.011DOI Listing
March 2016

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 6;374(4):311-22. Epub 2015 Dec 6.

From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513257DOI Listing
January 2016

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

N Engl J Med 2015 Dec 6;373(25):2425-37. Epub 2015 Dec 6.

From the University of Texas MD Anderson Cancer Center, Houston (J.A.B.); Azienda Ospedaliera Niguarda Cà Granda (A.T.) and Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele (P.G.), Milan, and the Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (G.G.) - all in Italy; Wilmot Cancer Institute, University of Rochester, Rochester, NY (P.M.B.); Medical University of Lodz and Copernicus Memorial Hospital, Lodz (T.R.), the Department of Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice (S.G.), and the Department of Hematology, University Clinical Center of Medical University of Gdansk, Gdansk (A.H.) - all in Poland; Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv (O.B.), and Hadassah University Hospital, Hebrew University Medical School, Jerusalem (A.P.) - both in Israel; Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds (P.H.), Kings College Hospital, London (S.D.), Royal Bournemouth Hospital, Bournemouth (H.M.), and University of Oxford, Oxford (A.S.) - all in the United Kingdom; Washington University School of Medicine, St. Louis (N.L.B.); Jiangsu Province Hospital, Nanjing, China (J.L.); North Shore Hospital, Auckland, New Zealand (D. Simpson); Stanford University School of Medicine, Stanford (S.C.), City of Hope National Medical Center, Duarte (T.S.), Pharmacyclics, Sunnyvale (D. Suri, M.C., F.C., L.S., D.F.J.), and Moores Cancer Center, University of California, San Diego, San Diego (T.J.K.) - all in California; St. Vincent's Hospital, University of Melbourne (H.Q.), and Peter MacCallum Cancer Centre and St. Vincent's Hospital (C.S.T.), Melbourne, VIC, Australia; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine (Z.M.); Norton Cancer Institute, Louisville, KY (D.A.S.);

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809PMC
December 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.

Haematologica 2015 Jul 10;100(7):945-54. Epub 2015 Apr 10.

Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA CLL Research Consortium, and Department of Medicine, University of California, San Diego, La Jolla, CA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.122069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486229PMC
July 2015

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.

EBioMedicine 2015 Jun 29;2(6):572-82. Epub 2015 Apr 29.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-1402, USA ; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2015.04.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535165PMC
June 2015

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

Clin Lymphoma Myeloma Leuk 2015 Jun;15 Suppl:S167-9

Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.02.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548279PMC
June 2015

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.

Proc Natl Acad Sci U S A 2015 Apr 18;112(14):4322-7. Epub 2015 Mar 18.

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210; College of Pharmacy, The Ohio State University, Columbus, OH 43210

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1503587112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394264PMC
April 2015

Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers.

PLoS Comput Biol 2015 Mar 13;11(3):e1004105. Epub 2015 Mar 13.

Moores Cancer Center, University of California San Diego, La Jolla, California, United States of America; Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, California, United States of America; Institute for Genomic Medicine, University of California San Diego, La Jolla, California, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pcbi.1004105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358997PMC
March 2015

Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.

Hum Gene Ther 2015 Jan;26(1):14-25

1 Moores Cancer Center, University of California-San Diego , La Jolla, CA 92093-0820.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/hum.2014.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303189PMC
January 2015